Mallinckrodt Pharmaceuticals Announces Executive Appointments
Company Rounds Out Senior Leadership Team
DUBLIN--(BUSINESS WIRE)--Oct. 24, 2013--
plc (NYSE: MNK), a global specialty pharmaceuticals company, today
announced three appointments to the Company’s senior management team.
This will round out Mallinckrodt’s executive leadership and help drive
the Company’s strategic focus toward growing its core business as a
specialty pharmaceutical company. The newly appointed executives, all of
whom are new to the Company, have served at some of the most prestigious
companies in the health care and pharmaceutical field, and together they
have a collective 70-plus years of experience in the industry.
Hugh O’Neill has joined the Company and will serve as Senior Vice
President and President of Specialty Pharmaceuticals. Most recently, Mr.
O’Neill held various commercial leadership positions at Sanofi,
including Vice President, Commercial Excellence; General Manager;
President of Sanofi Canada; and Vice President of Market Access and
Business Development. He has also been in positions of leadership at
Sandoz Pharmaceuticals, Forest Laboratories, Novartis Pharmaceuticals,
Gary Phillips has joined the Company as Senior Vice President and Chief
Strategy Officer, overseeing Strategy, Portfolio Management, Business
Development and Licensing, Market Analytics and Alliance Management.
Most recently, Dr. Phillips was head of Global Health and Healthcare
Industries for the World Economic Forum in Geneva, Switzerland. Prior to
that, he was President of Reckitt Benckiser Pharmaceuticals North
America and President of US Pharmaceuticals and Surgical at Bausch &
Lomb. He has also been in positions of leadership at Merck Serono,
Novartis Pharmaceuticals, Wyeth-Ayerst, and Gensia Pharmaceuticals.
Mario Saltarelli has joined the Company as Senior Vice President and
Chief Science Officer, and will lead the recently consolidated functions
of Research and Development (R&D), Medical Affairs, and Regulatory
Affairs. Dr. Saltarelli comes to Mallinckrodt having recently served as
Senior Vice President, R&D, at Shire plc. Prior to that, he held
positions of responsibility in R&D at Abbott Laboratories and Pfizer,
and academic posts in the Department of Neurology at the Emory
University School of Medicine in Atlanta.
“I'm delighted to welcome Hugh, Gary and Mario to Mallinckrodt and to
our senior management team,” said Mark Trudeau, President and CEO of
Mallinckrodt Pharmaceuticals. “Their combined years of experience and
great strengths in their respective fields will help solidify our
position as a science-based company, allow us to expand our core
specialty pharmaceutical business, and position us to be more
competitive in the marketplace. I am confident that, with these
important additions to our senior leadership team, we are well
positioned to unlock our potential to become a competitive leader in the
specialty pharmaceutical space. I greatly look forward to working with
Mallinckrodt is a leading global specialty pharmaceuticals business that
develops, manufactures, markets, and distributes specialty
pharmaceutical products and medical imaging agents. The Company’s
Specialty Pharmaceuticals segment includes branded and generic drugs,
and the Global Medical Imaging segment includes contrast media and
nuclear imaging agents. Mallinckrodt has approximately 5,500 employees
worldwide with sales in roughly 70 countries. The company’s 2012 revenue
totaled 2.1 billion. To learn more about Mallinckrodt, please visit www.mallinckrodt.com.
Source: Mallinckrodt plc
Lynn Phillips, 314-654-3263
Senior Vice President, Communications
Vice President, Investor Relations